VEEVA-SYSTEMS-INC.
19.5.2020 09:02:14 CEST | Business Wire | Press release
2020 Veeva R&D Summit Europe — Veeva Systems (NYSE: VEEV) today announced MyVeeva, a new application for clinical research sites. With capabilities for virtual visits, patient adherence, ePRO, eConsent, eSource and an easy to use patient portal, MyVeeva will make it easier for clinical research sites to deliver a patient-centric and paperless clinical trial experience for patients and sponsors. MyVeeva is free for clinical research sites and integrates seamlessly with Veeva SiteVault .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005377/en/
“There is a pressing need for clinical solutions that reduce the burden on patients participating in trials and make study execution easier for sites,” said Jessica Collins, program director for investigator-initiated clinical trials at Vanderbilt University Medical Center. “Having the ability to conduct parts of a study remotely is key to a better patient experience and speeding study conduct. It’s a crucial shift for the industry and I appreciate the innovation Veeva is bringing to this important area.”
MyVeeva enables patients, doctors, and clinical research coordinators to collaborate remotely with advanced audio and video capabilities, reducing the need for in-person visits. Clinical researchers can collect and record patient data electronically; make it more convenient for patients to report on treatment outcomes; easily share information electronically and get patient consent; and help patients take medications and adhere to their treatment regimens.
“COVID-19 created even greater urgency for clinical trials to become more virtual and deliver a safe, convenient patient experience,” said Henry Levy, general manager of Vault CDMS , site, and patient solutions at Veeva. “Enabling home-based trial visits with MyVeeva can advance the move to more patient-centric and paperless trials. We are excited to partner with the industry to help improve the clinical trial process for sponsors, sites, and patients.”
Sites will have the flexibility to use MyVeeva with Veeva SiteVault and Veeva Vault Clinical applications, as well as third-party clinical applications. MyVeeva is planned for availability in December 2020.
MyVeeva is part of the Veeva Clinical Network, a set of solutions that brings together sponsors, sites, and patients to accelerate clinical research. In addition to MyVeeva, Veeva today announced Veeva Vault Site Connect , a new application that connects sponsors and clinical research sites during trials. Together with Veeva Vault Clinical Suite , Veeva is the first and only company providing solutions that help sponsors, sites, and patients share and view information during a clinical trial. For more information on how Veeva will enable patient-centric trials, contact info@veeva.com .
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005377/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PANECO to Exhibit at EuroShop 2026 -- Seeking Global Sales Partners for Sustainable Materials Made from Textile Waste --9.2.2026 08:00:00 CET | Press release
Japanese-Made Textile Recycling Boards Supporting Sustainability in Retail PANECO®, a textile circularity and sustainable materials platform developed by WORKSTUDIO Co., Ltd. (Tokyo, Japan), will exhibit at EuroShop 2026, held in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203145499/en/ Textile Recycling Board | PANECO Visitors to EuroShop are actively searching for sustainable materials that can be implemented in commercial spaces and furniture. Across Europe and globally, demand for the practical implementation of sustainable materials is rapidly increasing. In this environment, materials are expected to be not only environmentally responsible, but also scalable, reliable, and commercially viable. In response to this market demand, PANECO® transforms textile waste into high-quality recycled boards, offering sustainable solutions for commercial spaces and furniture. These materials are designed fo
Tigo Energy EI Residential Solar-plus-Storage Solution Certified with Romanian Grid Operators9.2.2026 06:00:00 CET | Press release
With approval from Distribuție Energie Electrică România (DEER), Distribuție Oltenia, and Rețele Electrice, Tigo expands offering in one of Europe’s fastest-growing residential solar markets. Tigo Energy, Inc. (NASDAQ: “TYGO”) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced the successful certification of the Tigo EI Residential solar-plus-storage solution with Romanian distribution system operators, further expanding market reach of Tigo products across Europe. Following the successful completion of their respective grid-compliance and certification procedures with Distribuție Energie Electrică Romania (DEER), Distribuție Oltenia, and Rețele Electrice, single-phase and three-phase configurations of the EI Residential solution are now fully listed and approved for use in the Romanian market. With 2026 expected to be another strong year for solar growth nationally, the Tigo EI Residential system becomes an important addition
Levi’s® Brand Debuts “Behind Every Original” Campaign With Super Bowl Film Highlighting Backstories and Backsides9.2.2026 01:38:00 CET | Press release
The Levi’s® brand today launched “Behind Every Original,” a bold new global campaign that celebrates the people who push culture forward — with one cheeky twist. Debuting during the Super Bowl with the anthem film “Backstory,” directed by Kim Gehrig, the Levi’s® brand flips expectations by showcasing both celebrity icons and everyday Originals exclusively from the backside, letting them share their game-changing Levi’s® backstory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260208761156/en/ Doechii Why the backside? Because it's the most iconic point of view of Levi’s® jeans. The arcuate stitching, silhouette and the Red Tab™ instantly signal originality. For over 150 years, Levi’s® jeans have been the uniform of cultural catalysts who step off the beaten path and shape what comes next in music, sport, fashion and art. They have been the uniform of the movements and moments that have changed the world and shaped culture —
DCO Concludes 5th General Assembly with Adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity7.2.2026 16:41:00 CET | Press release
The Digital Cooperation Organization (DCO) has concluded its fifth General Assembly, with Member States adopting the Kuwait Declaration on Responsible AI for Global Digital Prosperity and agreeing on actions to advance inclusive, trusted, and scalable digital transformation in the AI age. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207972901/en/ DCO concludes 5th General Assembly with adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity (Photo: AETOSWire) Convened on 4–5 February 2026 under the Presidency of the State of Kuwait, the General Assembly brought together Ministers and Representatives of Member States, alongside Observers, partners, and guest countries, to review progress against the DCO 4-Year Agenda (2025–2028), take joint decisions on multilateral initiatives, and translate shared ambition on AI into delivery. Ministers and representatives reaffirmed their commitment to inclu
Rapid Medical™’s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER™ 13 in Medium Vessel Stroke6.2.2026 20:30:00 CET | Press release
TIGERTRIEVER™ 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic strokes Rapid Medical™, a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior brain tissue reperfusion with an excellent safety profile when compared with medical management in medium vessel occlusion (MVO) stroke. The findings were presented in the main closing session at the 2026 International Stroke Conference (ISC). Top-line results showed that the TIGERTRIEVER™ 13 arm demonstrated 3x more successful reperfusion without symptomatic intracranial hemorrhage (sICH) compared to medical management–86.3% vs 27.7% (p < 0.001). Notably, zero sICH events were reported in the randomized treatment arm treated with TIGERTRIEVER 13. By comparison, sICH rates rep
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom